China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
CAMBRIDGE, Mass., Feb. 27, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation is scheduled for 9:20 AM ET on March 7, 2017.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
